<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634789</url>
  </required_header>
  <id_info>
    <org_study_id>B2311014</org_study_id>
    <secondary_id>3115B1-1146</secondary_id>
    <nct_id>NCT01634789</nct_id>
  </id_info>
  <brief_title>A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene (Bza) Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens (ce) in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate 3 test formulations relative to a reference
      formulation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated on 10 December 2012 due to low enrollment. The decision to terminate
    the study was not based on safety or efficacy issues.
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to Last Observable Concentration (AUCT)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination-phase Half-life (t1/2)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability (F)</measure>
    <time_frame>0, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 9, 16, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Treatment 1: bazedoxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Treatment 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment 2: bazedoxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment 3: bazedoxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Treatment 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Treatment: bazedoxifene/conjugated estrogens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bazedoxifene</intervention_name>
    <description>20 mg oral tablet, single dose</description>
    <arm_group_label>Test Treatment 1: bazedoxifene</arm_group_label>
    <other_name>TSE-424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bazedoxifene</intervention_name>
    <description>20 mg oral tablet, single dose</description>
    <arm_group_label>Test Treatment 2: bazedoxifene</arm_group_label>
    <other_name>TSE-424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bazedoxifene</intervention_name>
    <description>20 mg oral tablet, single dose</description>
    <arm_group_label>Test Treatment 3: bazedoxifene</arm_group_label>
    <other_name>TSE-424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bazedoxifene/conjugated estrogens</intervention_name>
    <description>20 mg / 0.625 mg oral tablet, single dose</description>
    <arm_group_label>Reference Treatment: bazedoxifene/conjugated estrogens</arm_group_label>
    <other_name>BZA/CE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy postmenopausal women

          -  Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight &gt;= 50 kg

        Exclusion Criteria:

          -  Pregnant or nursing females; females of childbearing potential
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311014&amp;StudyName=A%20Pilot%20Bioavailability%20Study%20of%203%20Test%20Tablet%20Formulations%20of%20Bazedoxifene%20Compared%20with%20A%20Reference%20Tablet%20Formulation%20of%20Bazedoxifene/C</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Bazedoxifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

